Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer

NCT03007992 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
9
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Johannes Gutenberg University Mainz

Collaborators